Zuraw Bruce L
University of California San Diego, La Jolla, CA 92093-0732, USA.
Immunol Allergy Clin North Am. 2006 Nov;26(4):691-708. doi: 10.1016/j.iac.2006.09.007.
Advances in our understanding of the molecular mechanisms underlying hereditary angioedema (HAE) have led to the development of new treatment modalities. Five new drugs for the treatment of HAE are currently undergoing clinical testing in the United States. These novel therapeutics can be divided into two groups: drugs that replace C1 inhibitor (C1INH) functional activity and drugs that abrogate the bradykinin-mediated increase in vascular permeability associated with HAE attacks. The first group includes two plasma-derived C1INH concentrates as well as a recombinant transgenic human C1INH protein, and the second group includes an engineered plasma kallikrein inhibitor as well as a B2 bradykinin receptor antagonist. This article reviews the rationale, development, and potential use of these novel therapeutics.
我们对遗传性血管性水肿（HAE）潜在分子机制认识的进展，促成了新治疗方式的发展。目前有五种治疗HAE的新药正在美国进行临床试验。这些新型疗法可分为两类：替代C1抑制剂（C1INH）功能活性的药物，以及消除缓激肽介导的与HAE发作相关的血管通透性增加的药物。第一类包括两种血浆源性C1INH浓缩物以及一种重组转基因人C1INH蛋白，第二类包括一种工程化血浆激肽释放酶抑制剂以及一种B2缓激肽受体拮抗剂。本文综述了这些新型疗法的理论依据、研发情况及潜在用途。
